The University College London Hospitals NHS Foundation Trust (UCLH) has begun human trials for an mRNA vaccine for the skin cancer melanoma, which impacts around 132K around the world annually.
The vaccine, which uses the same technology as some of the COVID jabs, is made by companies Moderna and Merck Sharp and Dohme (MSD). It's personalized, meaning it's built to target only the specific genetic makeup of an individual's tumor.